Clinical Outcomes of an Enhanced and Conventional Monofocal IOL in Patients with Early and Intermediate Dry Age-Related Macular Degeneration

早期和中期干性年龄相关性黄斑变性患者中增强型和传统单焦点人工晶状体的临床结果

阅读:2

Abstract

PURPOSE: To compare the performance of an enhanced and conventional monofocal IOL in eyes with early and intermediate age-related macular degeneration (AMD). METHODS: This retrospective study compared one-month postoperative outcomes of patients bilaterally implanted with TECNIS Eyhance IOL (ICB00 group) or TECNIS Monofocal IOL (ZCB00 group). All patients underwent cataract surgery with pre-existing early or intermediate dry AMD. Outcome measures were monocular and binocular uncorrected distance (UDVA), intermediate (UIVA) and near (UNVA) visual acuity, monocular corrected distance visual acuity (CDVA), and refractive outcomes. Monocular visual acuities and refractive predictability were calculated for the dominant eye of each patient. RESULTS: The ICB00 group comprised 143 eyes of 143 patients, while 164 eyes of 164 patients were included in the ZCB00 group. Preoperative characteristics were comparable between the two groups. There was no significant difference in postoperative refractive predictability, with 87.4% and 89.6% of eyes within 0.50 D of emmetropia in the ICB00 and ZCB00 groups, respectively (p=0.54). No difference was found in postoperative UDVA or CDVA between the groups. Both monocular and binocular UIVA were significantly better in the ICB00 group (monocular UIVA: 0.32±0.19 vs 0.42±0.22 logMAR, p<0.001; binocular UIVA: 0.25±0.18 vs 0.36±0.17 logMAR, p<0.001). Postoperative UNVA was also better with the ICB00 IOL (monocular UNVA: 0.58±0.16 vs 0.69±0.20 logMAR, p<0.001; binocular UNVA: 0.50±0.16 vs 0.63±0.17 logMAR, p<0.001). CONCLUSION: ICB00 IOL enhanced intermediate and near vision in patients with AMD while achieving the same level of corrected and uncorrected distance visual acuity.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。